Antidepressant therapy with milnacipran and venlafaxine

Lucilla Mansuy
Pierre Fabre Médicament, Toulouse, France

Abstract: Specific serotonin norepinephrine reuptake inhibitors (SNRIs) have been described as “better tolerated tricyclic antidepressants” or as “boosted” selective serotonin reuptake inhibitors (SSRIs). Venlafaxine has become a therapeutic reference treatment for major depression. Although less widely studied, indirect comparisons with another SNRI, milnacipran, suggest an equivalent efficacy. This paper discusses these indirect comparisons and the recently published first double-blind, head-to-head comparison. Venlafaxine has potency at serotonin transporters which is about 30-fold greater than that at norepinephrine transporters while milnacipran has a similar potency at each transporter. Thus, at low doses, venlafaxine acts essentially as a SSRI, with significant noradrenergic activity only occurring at higher doses. To overcome the problem of the differing profile of venlafaxine at increasing doses, the first head-to-head study compared the therapeutic effects and tolerability of the two antidepressants when flexibly titrated to the high dose of 200 mg/day. The study showed that the two SNRIs have similar efficacy and safety profiles. Both drugs produced about 42% remissions at the end of the 20-week study. The most frequent adverse events in both groups were nausea, dizziness, headache, and sweating. Certain specific differences in tolerability are discussed.

Keywords: milnacipran, venlafaxine, antidepressant efficacy, tolerability, dose-titration

Introduction

Major depression is a common psychiatric condition with a prevalence of 5%-13% in the general population. Despite its prevalence and its consequences for both individuals and society in general, depression is only correctly diagnosed in 50% of cases, and less than 10% of patients with depression receive appropriate antidepressant treatment of adequate dose and duration. It is now generally accepted that the minimum duration of antidepressant treatment in order to prevent relapse of the current episode is 6 months. Few randomized, double-blind, clinical studies of antidepressants, however, extend for this length of time.

Most antidepressants act to increase the synaptic concentration of serotonin (5-hydroxytryptamine, 5-HT) and/or norepinephrine (NE), generally by inhibiting the reuptake of one or both of these neurotransmitters. Serotonin and norepinephrine reuptake inhibitors (SNRIs) combine the efficacy of the tricyclic antidepressants (TCAs) with the tolerability of the selective serotonin reuptake inhibitors (SSRIs). Milnacipran (Izel®) and venlafaxine (Effexor®) are both SNRIs, although they differ in their selectivity inhibition of NE and 5-HT reuptake. Milnacipran has the most balanced ratio of potency for reuptake inhibition of the two neurotransmitters (5HT:NE 1:1.16).

One study has shown milnacipran to inhibit NE reuptake with greater potency than...
SSRIs concluded a superior efficacy for all the dual-action of studies comparing newer dual-action antidepressants with ramine, as having “definite superior efficacy”. Juxtaposition tioned above, venlafaxine was classified, along with clomip-

The recommended starting dose for venlafaxine is 75 mg/day, SNRIs is the choice of dose. In the FDA labeling for Effexor venlafaxine. One difficulty of directly comparing these two have been no direct comparisons between milnacipran and efficacy across all measures.

Venlafaxine is a widely used antidepressant and has recently been described as a reference treatment for major depression. In a global analysis of all antidepressants men-

A post hoc analysis has shown that milnacipran has greater efficacy than SSRIs in more severely depressed patients. A global analysis of all dual-acting antidepressants concluded that three antidepressants, ie, milnacipran, duloxetine, and mirtazapine, had “probable superior efficacy” compared with the SSRIs.

Venlafaxine has a 30-fold greater potency for 5-HT. TCAs remain the “gold standard” for antidepressant efficacy, although their poor tolerability complicates their use at fully effective doses. Milnacipran has an efficacy comparable with that of the TCAs including clomipramine. 

A first direct comparison of milnacipran and venlafaxine (immediate-release) was carried out at doses flexibly titrated up to a maximum of 200 mg/day for each compound. In addition, because in clinical practice a major objective is to achieve a long-lasting remission from depression, the study was carried out over a duration of 24 weeks. The choice of the IR formulation of venlafaxine rather than the XR (extended-release) formulation was probably chosen to enable identical twice-daily dosing, although this is not mentioned in the publication.

Milnacipran has a similar effect on both serotonin and norepinephrine reuptake and thus acts as an SNRI at all doses. The recommended dose of milnacipran in major depression is 100 mg/day, although various studies carried out with doses 150–300 mg/day have suggested that some patients may benefit from higher doses. These studies have shown that these higher doses of milnacipran are well tolerated by most patients. No new adverse effects are seen at higher doses.

Milnacipran and venlafaxine IR flexibly titrated to 200 mg/day

The first direct comparison of milnacipran and venlafaxine IR (immediate-release) was carried out over a duration of 24 weeks. The choice of the IR formulation of venlafaxine rather than the XR (extended-release) formulation was probably chosen to enable identical twice-daily dosing, although this is not mentioned in the publication.

The recommended dose of milnacipran in major depression is 100 mg/day, but studies carried out at doses of 150–300 mg/day suggest that some patients may benefit from higher doses and milnacipran is frequently used at these doses. The recommended dose range for venlafaxine in outpatients is 75–225 mg/day. Thus, the objective of this study was to explore the efficacy and long-term safety/tolerability of milnacipran and venlafaxine administered in an outpatient setting at doses of up to 200 mg/day in patients suffering from a major depressive episode.

This multicenter, randomized, double-blind study was carried out in 195 adult outpatients presenting with an episode of recurrent, unipolar, moderate-to-severe (Montgomery-Asberg Depression Rating Scale [MADRS] score ≥23) major depressive disorder. During the first 4 weeks of the study, the dose of each antidepressant was uptitrated (days 1–3, 25 mg/day; days 4–6, 50 mg/day; days 7–13, 100 mg/day; days 14–28, 150 mg/day). At day 28, at the clinician’s discretion, the dose was maintained at 150 mg/day, reduced to 100 mg/day, or increased to 200 mg/day. At the end of the 24-week study, the dose was downtitrated by 50 mg/day every 5 days. The daily doses were administered in two identical doses morning and evening, except the initial dose of 25 mg/day (one morning dose only) and the dose of 150 mg/day (50 mg morning and 100 mg evening). Depressive symptoms were assessed weekly using the MADRS.

This multicenter, randomized, double-blind study was carried out in 195 adult outpatients presenting with an episode of recurrent, unipolar, moderate-to-severe (Montgomery-Asberg Depression Rating Scale [MADRS] score ≥23) major depressive disorder. During the first 4 weeks of the study, the dose of each antidepressant was uptitrated (days 1–3, 25 mg/day; days 4–6, 50 mg/day; days 7–13, 100 mg/day; days 14–28, 150 mg/day). At day 28, at the clinician’s discretion, the dose was maintained at 150 mg/day, reduced to 100 mg/day, or increased to 200 mg/day. At the end of the 24-week study, the dose was downtitrated by 50 mg/day every 5 days. The daily doses were administered in two identical doses morning and evening, except the initial dose of 25 mg/day (one morning dose only) and the dose of 150 mg/day (50 mg morning and 100 mg evening). Depressive symptoms were assessed weekly using the MADRS.
Of the 195 patients randomized (milnacipran 97, venlafaxine 98), 134 completed 24 weeks of treatment (milnacipran 60, venlafaxine 74). In both groups, the main reason for premature withdrawal was adverse events (AEs, 51% on milnacipran, 42% on venlafaxine). The other reasons for premature withdrawal, such as lack of efficacy or patient decision after recovery, were not stated, so it is not possible to analyze the dropout data in detail.

The baseline characteristics of the patients (Table 1) were similar in both groups, except that there were significantly more patients with a severe depressive episode in the milnacipran group (63.3% versus 54% in the venlafaxine group). Most patients (87%) had had previous depressive episodes which had been treated with antidepressants. The mean baseline MADRS score of 31.0 in the overall population indicated moderate to severe intensity of the depression.

At the end of the titration period, approximately 90% of patients were taking an antidepressant dose of either 150 or 200 mg/day (Table 2). This percentage remained constant for both antidepressants through to the end of the study.

The MADRS score decreased progressively throughout the study and was comparable in the two treatment groups (Figure 1). The rate of response (≥50% reduction in initial MADRS score) and remission (a MADRS score ≤10, Figure 2) was not clinically or statistically different between the two treatment groups at week 8 or week 24. Rates of response and remission were also similar with both antidepressants in a subgroup of patients with a severe depressive episode (n = 104, Table 3) and in patients with a measurable suicide risk (“low” or “moderate” according to the Mini International Neuropsychiatric Interview) at baseline (n = 75, Table 3).

In the vast majority of cases, the therapeutic benefit achieved at week 8 was maintained over the long term. Overall, 93% of responders at week 8 were also responders at week 24 (milnacipran, 95%, venlafaxine 87%), while 89.3% of the patients in remission at week 8 were also in remission at week 24 (milnacipran 87%, venlafaxine 92%).

During treatment, AEs were reported by 72% patients in the milnacipran group and 74% patients in the venlafaxine group. In both groups, the most common treatment-emergent AEs (occurring in ≥10% of patients) were nausea, headache, dizziness, constipation, hyperhidrosis, palpitations, and dry mouth (Figure 3). After the end of treatment during the down-titration, the incidence of AEs was greater in the venlafaxine group (14% versus 7% in the milnacipran group). In males, dysuria was experienced only in the milnacipran group (20%), while orgasmic disorders were only reported in the venlafaxine group (17%). Most of the AEs occurred during the first 3 weeks of treatment, and 85% of them were of mild or moderate severity. Five patients in the milnacipran group and seven patients in the venlafaxine group experienced at least one serious AE. Only three serious AEs (all in the venlafaxine group) were considered to be possibly related to the study treatment (one worsening depression, one anxiety related to an overdose of venlafaxine, and one biliary colic).

Dysuria during treatment with milnacipran has been reported previously. Dysuria is also experienced with other antidepressants having a major impact on the noradrenergic system, such as reboxetine.

Orgasmic disorder was spontaneously reported in 17% of patients treated with venlafaxine but in no patients treated with milnacipran. The absence of sexual dysfunction with milnacipran is consistent with other studies, which

<table>
<thead>
<tr>
<th>Table 1 Demographic characteristics at baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Women (%)</td>
</tr>
<tr>
<td>Mean age (years) ± SD</td>
</tr>
<tr>
<td>Mean duration of current episode (months) ± SD</td>
</tr>
<tr>
<td>Patients with severe depressive episode (%)</td>
</tr>
<tr>
<td>Severity of suicide risk**</td>
</tr>
<tr>
<td>Low (%)</td>
</tr>
<tr>
<td>Moderate (%)</td>
</tr>
<tr>
<td>High (%)</td>
</tr>
<tr>
<td>MADRS (mean ± SD)</td>
</tr>
<tr>
<td>CGI-S (mean ± SD)</td>
</tr>
</tbody>
</table>

Notes: *Severe depressive episode as defined by DSM-IV; **Moderate or mild suicide risk determined using the MINI.

| Abbreviations: CGI-S, clinical global impressions scale; MADRS, Montgomery-Asberg depression rating scale; MINI, mini international neuropsychiatric interview; SD, standard deviation. |

<table>
<thead>
<tr>
<th>Table 2 Doses of antidepressants received by patients at the end of the titration period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>150–200 mg/day</td>
</tr>
<tr>
<td>150 mg/day</td>
</tr>
<tr>
<td>200 mg/day</td>
</tr>
</tbody>
</table>

At the end of treatment, the distribution of doses did not differ significantly from that at the end of the titration period in the two groups.
have shown that milnacipran does not cause treatment-emergent sexual dysfunction. Antidepressant-induced sexual dysfunction is generally thought to result from stimulation of 5-HT$_2$ receptors, although this is probably not the only mechanism. The absence of these effects with milnacipran, which also stimulates serotonergic transmission but does not act as an antagonist at 5-HT$_2$ receptors, suggests that sexual dysfunction induced via stimulation of postsynaptic 5-HT$_2$ receptors may be attenuated or completely blocked by simultaneous noradrenergic stimulation, although the mechanism of this effect remains to be elucidated.

The study discussed in this review shows that milnacipran and venlafaxine, when administered at flexible doses of up to 200 mg/day, have similar efficacy and safety profiles. There are, however, certain differences between the two SNRIs that were not explored in this study. Whereas milnacipran has no effect on any cytochrome (CYP) P450 enzyme, venlafaxine is a substrate for CYP2D6 which is responsible for its transformation into the active metabolite, desvenlafaxine. There is considerable polymorphism of CYP2D6, with nearly 10% of “slow metabolizers” in the Caucasian population. This property is likely to induce unexpected variation in therapeutic effect and tolerability. In addition, as stated in the FDA labeling, venlafaxine’s tolerability can be influenced by coadministration of drugs that inhibit CYP2D6, such as cimetidine and certain antipsychotics. A recent study has shown that venlafaxine intoxication frequently (in 46% of cases) occurs in the presence of drugs interacting at the

![Figure 1 MADRS total score (mean changes from baseline) over the first 8 weeks of treatment](image1)

**Notes:** The values are mean ± SEM of the observed case population (n = 60 milnacipran; n = 74 venlafaxine).

![Figure 2 Responders and remissions (MADRS) after 8 weeks](image2)

**Key:** filled columns = responders (≥50% reduction in initial MADRS score); hatched columns = remissions (MADRS score ≤ 10).

**Notes:** Values are based on the whole randomized population using the last observer carried forward method population (n = 97 milnacipran; n = 98 venlafaxine).
CYP P450 2D6 isoenzyme, resulting in higher venlafaxine concentrations.31

Finally, the two antidepressants vary considerably in terms of safety in overdose. Milnacipran has been shown to be safe in overdose, with doses as high as 2.8 g causing no serious effects and no mortality.32 No deaths have been reported following milnacipran overdose, with the exception of a case of multiple drug overdose where high blood levels of milnacipran, fluoxetine, norfluoxetine, sertraline, cyamemazine, nordiazepam, and oxazepam were found.33 In contrast, lethal consequences of venlafaxine overdose have been reported, with a frequency of over 34 per 1000 person-years. This was significantly greater than other antidepressants, including the TCAs.34 A study carried out in the UK showed that the fatal toxicity index (deaths/million prescriptions) of venlafaxine (13) was similar to that of TCAs such as amitriptyline (15).35 Another more recent fatal toxicity survey, however, showed greater toxicity for TCAs (13.8) than for venlafaxine (2.5), although the latter was considerably more toxic than the SSRIs (0.5).36 A prominent feature of cases of venlafaxine intoxication is the frequent presence (in 46% of cases) of drugs interacting at the CYP P450, resulting in higher venlafaxine concentrations.36

**Conclusion**

Indirect comparisons3-12 and everyday clinical experience has suggested that milnacipran and venlafaxine have similar efficacy. The first head-to-head comparison at a dose of 200 mg/day has confirmed this suggestion. The study also showed that concerns about tolerability at higher doses were unfounded. When the SNRIs were titrated flexibly over a period of 4 weeks, both milnacipran and venlafaxine were relatively well tolerated, with about 90% of patients achieving doses of 150 or 200 mg/day.

Venlafaxine has become a therapeutic reference for major depression.11 Although less widely studied, indirect comparisons and the head-to-head study discussed here show that milnacipran can be considered to be clinically equivalent to venlafaxine in terms of efficacy, with certain advantages when sexual dysfunction, overdose, or polymedication are of concern.

**Disclosure**

The author is employed by Pierre Fabre Médicament manufacturers of milnacipran.

**Table 3 Rates of response and remission**

<table>
<thead>
<tr>
<th>Patients with a severe depressive episode at inclusion</th>
<th>Responders (%)</th>
<th>Remissions (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Week 8</td>
<td>Week 24</td>
</tr>
<tr>
<td>Milnacipran</td>
<td>61.4</td>
<td>71.9</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>61.7</td>
<td>74.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients with measurable suicide risk at inclusion</th>
<th>Responders (%)</th>
<th>Remissions (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Week 8</td>
<td>Week 24</td>
</tr>
<tr>
<td>Milnacipran</td>
<td>65.8</td>
<td>71.1</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>59.5</td>
<td>64.9</td>
</tr>
</tbody>
</table>

**Notes:** *Severe depressive episode as defined by DSM-IV; **mild or moderate suicide risk determined using the MINI.

**References**


